Bisphenol A and estradiol are equipotent in antagonizing cisplatin-induced cytotoxicity in breast cancer cells

EW LaPensee, CR LaPensee, S Fox, S Schwemberger… - Cancer letters, 2010 - Elsevier
EW LaPensee, CR LaPensee, S Fox, S Schwemberger, S Afton, N Ben-Jonathan
Cancer letters, 2010Elsevier
Resistance to chemotherapy is a major problem facing breast cancer patients. Cisplatin, a
highly effective DNA-damaging drug, has shown only little success in breast cancer
treatment. We are reporting that low nanomolar doses of bisphenol A (BPA) or estradiol
antagonize cisplatin cytotoxicity in breast cancer cells, with their effects not mediated via
classical estrogen receptors. Although both compounds increase the expression of Bcl-2, a
Bcl-2 inhibitor completely blocked the protective effects of BPA while only partially affecting …
Resistance to chemotherapy is a major problem facing breast cancer patients. Cisplatin, a highly effective DNA-damaging drug, has shown only little success in breast cancer treatment. We are reporting that low nanomolar doses of bisphenol A (BPA) or estradiol antagonize cisplatin cytotoxicity in breast cancer cells, with their effects not mediated via classical estrogen receptors. Although both compounds increase the expression of Bcl-2, a Bcl-2 inhibitor completely blocked the protective effects of BPA while only partially affecting those of estradiol. Blockade of BPA and E2 actions should sensitize ER-negative breast tumors to anti-cancer drugs and allow for the inclusion of cisplatin in treatment regimens.
Elsevier